Abveris, Immunitas partner on mAbs discovery

By The Science Advisory Board staff writers

October 8, 2020 -- Abveris and Immunitas Therapeutics are partnering on the discovery of monoclonal antibodies (mAbs) to expand Immunitas' therapeutic pipeline.

Under the agreement, Abveris will utilize its proprietary DiversimAb mouse model in combination with its next-generation, B-cell screening platform, powered by the Beacon system from Berkeley Lights, to rapidly discover mAbs for use as research reagents and therapeutics for immuno-oncology applications.

The Immunitas team will leverage its single-cell genomics-based techniques for identifying novel therapeutic oncology targets.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.